<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>baseline. — Methodology</title>
<meta name="description" content="How we ranked 40 health metrics by ROI. Three scoring axes, source hierarchy, and why certain popular metrics didn't make the cut.">
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Barlow+Condensed:wght@400;600;700;800&family=DM+Sans:wght@300;400;500;700&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
*, *::before, *::after { margin: 0; padding: 0; box-sizing: border-box; }

:root {
  --bg: #08080a;
  --bg-elevated: #0e0e11;
  --border: #181820;
  --text: #f0f0f0;
  --text-muted: #7a7a88;
  --text-dim: #3e3e4a;
  --red: #c83c3c;
  --red-dim: rgba(200, 60, 60, 0.10);
  --font-display: 'Barlow Condensed', sans-serif;
  --font-body: 'DM Sans', -apple-system, sans-serif;
  --font-mono: 'JetBrains Mono', monospace;
}

html { scroll-behavior: smooth; }

body {
  background: var(--bg);
  color: var(--text);
  font-family: var(--font-body);
  line-height: 1.6;
  -webkit-font-smoothing: antialiased;
}

a { color: inherit; text-decoration: none; }

.container {
  max-width: 720px;
  margin: 0 auto;
  padding: 0 28px;
}

/* Header */
.header {
  padding: 48px 0 0;
}

.header .logo {
  font-family: var(--font-display);
  font-size: 1.1rem;
  font-weight: 700;
  text-transform: lowercase;
  letter-spacing: -0.5px;
}

.header .logo .period { color: var(--red); }

.header .logo a:hover { opacity: 0.7; }

.back-link {
  font-family: var(--font-mono);
  font-size: 0.72rem;
  color: var(--text-dim);
  display: inline-block;
  margin-top: 12px;
  transition: color 0.2s;
}

.back-link:hover { color: var(--text-muted); }

/* Page title */
.page-title {
  padding: 64px 0 48px;
}

.page-title h1 {
  font-family: var(--font-display);
  font-size: clamp(2rem, 5vw, 2.8rem);
  font-weight: 800;
  text-transform: uppercase;
  letter-spacing: -0.5px;
  line-height: 1.05;
  margin-bottom: 16px;
}

.page-title .subtitle {
  font-size: 1rem;
  color: var(--text-muted);
  max-width: 560px;
  line-height: 1.65;
}

/* Content sections */
.method-section {
  padding: 48px 0;
  border-top: 1px solid var(--border);
}

.method-section h2 {
  font-family: var(--font-display);
  font-size: 1.4rem;
  font-weight: 700;
  text-transform: uppercase;
  letter-spacing: -0.3px;
  margin-bottom: 24px;
}

.method-section h3 {
  font-family: var(--font-display);
  font-size: 1.05rem;
  font-weight: 700;
  text-transform: uppercase;
  letter-spacing: -0.2px;
  margin-top: 32px;
  margin-bottom: 12px;
}

.method-section p {
  font-size: 0.92rem;
  color: var(--text-muted);
  line-height: 1.75;
  margin-bottom: 16px;
}

.method-section p:last-child { margin-bottom: 0; }
.method-section strong { color: var(--text); }

/* Axes */
.axes {
  display: flex;
  flex-direction: column;
  gap: 16px;
  margin: 24px 0;
}

.axis {
  padding: 20px 24px;
  background: var(--bg-elevated);
  border: 1px solid var(--border);
  border-radius: 6px;
}

.axis .axis-num {
  font-family: var(--font-mono);
  font-size: 0.65rem;
  color: var(--text-dim);
  letter-spacing: 0.1em;
  margin-bottom: 6px;
}

.axis .axis-name {
  font-family: var(--font-display);
  font-size: 1.05rem;
  font-weight: 700;
  text-transform: uppercase;
  margin-bottom: 8px;
}

.axis .axis-desc {
  font-size: 0.85rem;
  color: var(--text-muted);
  line-height: 1.6;
}

/* Source hierarchy */
.hierarchy {
  display: flex;
  flex-direction: column;
  gap: 0;
  margin: 24px 0;
  font-family: var(--font-mono);
  font-size: 0.78rem;
}

.hierarchy-row {
  display: flex;
  align-items: center;
  gap: 16px;
  padding: 12px 0;
  border-bottom: 1px solid rgba(255,255,255,0.04);
}

.hierarchy-row:last-child { border-bottom: none; }

.hierarchy-rank {
  color: var(--text-dim);
  width: 24px;
  flex-shrink: 0;
}

.hierarchy-type {
  flex: 1;
  color: var(--text);
}

.hierarchy-bar {
  width: 80px;
  height: 3px;
  background: rgba(255,255,255,0.06);
  border-radius: 2px;
  overflow: hidden;
}

.hierarchy-bar .fill {
  height: 100%;
  background: var(--text);
  border-radius: 2px;
}

/* Full ranking table */
.rank-table {
  width: 100%;
  border-collapse: separate;
  border-spacing: 0;
  margin: 24px 0;
}

.rank-table th {
  font-family: var(--font-mono);
  font-size: 0.65rem;
  font-weight: 500;
  color: var(--text-dim);
  letter-spacing: 0.08em;
  text-transform: uppercase;
  text-align: left;
  padding: 0 0 12px;
  border-bottom: 1px solid rgba(255,255,255,0.08);
}

.rank-table td {
  padding: 12px 0;
  font-size: 0.85rem;
  border-bottom: 1px solid rgba(255,255,255,0.04);
  vertical-align: top;
}

.rank-table td:first-child {
  font-family: var(--font-mono);
  font-size: 0.75rem;
  color: var(--text-dim);
  width: 32px;
}

.rank-table td:nth-child(2) { color: var(--text); font-weight: 500; }
.rank-table td:nth-child(3) { font-family: var(--font-mono); font-size: 0.78rem; color: var(--text-muted); white-space: nowrap; }
.rank-table td:nth-child(4) { color: var(--text-muted); font-size: 0.82rem; line-height: 1.55; padding-left: 16px; }

.rank-table .tier-header td {
  padding-top: 32px;
  font-family: var(--font-display);
  font-weight: 700;
  font-size: 0.85rem;
  text-transform: uppercase;
  letter-spacing: 1px;
  color: var(--text-dim);
  border-bottom: 1px solid rgba(255,255,255,0.08);
}

/* Counterproductive callout */
.counter-list {
  margin: 20px 0;
}

.counter-item {
  display: flex;
  gap: 14px;
  padding: 14px 0;
  border-bottom: 1px solid rgba(255,255,255,0.04);
}

.counter-item:last-child { border-bottom: none; }

.counter-icon {
  font-family: var(--font-mono);
  font-size: 0.72rem;
  color: var(--red);
  flex-shrink: 0;
  margin-top: 2px;
}

.counter-text {
  font-size: 0.85rem;
  color: var(--text-muted);
  line-height: 1.6;
}

.counter-text strong { color: var(--text); }

/* Sources */
.sources {
  font-family: var(--font-mono);
  font-size: 0.72rem;
  color: var(--text-dim);
  line-height: 1.8;
}

/* CTA */
.method-cta {
  padding: 80px 0;
  text-align: center;
  border-top: 1px solid var(--border);
}

.method-cta h2 {
  font-family: var(--font-display);
  font-size: 1.8rem;
  font-weight: 800;
  text-transform: uppercase;
  margin-bottom: 12px;
}

.method-cta p {
  font-size: 0.9rem;
  color: var(--text-muted);
  margin-bottom: 28px;
}

.method-cta .cta-btn {
  display: inline-block;
  padding: 13px 28px;
  background: var(--text);
  color: var(--bg);
  border-radius: 5px;
  font-family: var(--font-body);
  font-weight: 700;
  font-size: 0.85rem;
  transition: opacity 0.2s;
}

.method-cta .cta-btn:hover { opacity: 0.85; }

/* Footer */
footer {
  padding: 48px 0;
  border-top: 1px solid var(--border);
  text-align: center;
}

footer p {
  font-family: var(--font-mono);
  font-size: 0.72rem;
  color: var(--text-dim);
  line-height: 2;
}

@media (max-width: 600px) {
  .page-title { padding: 48px 0 32px; }
  .method-section { padding: 36px 0; }
  .rank-table td:nth-child(4) { display: none; }
}
</style>
</head>
<body>

<div class="container">
  <div class="header">
    <div class="logo"><a href="/baseline/">baseline<span class="period">.</span></a></div>
    <a href="/baseline/" class="back-link">&larr; Back to home</a>
  </div>
</div>

<div class="container">
  <div class="page-title">
    <h1>Methodology.</h1>
    <p class="subtitle">We ranked 40 health metrics by ROI — the signal strength of each measurement weighed against what it costs and whether knowing the number actually changes what you do. Here's how.</p>
  </div>
</div>

<div class="container">

  <!-- Scoring Axes -->
  <div class="method-section">
    <h2>Three scoring axes.</h2>
    <p>Every metric was evaluated on three dimensions. A metric has to score well on all three to make the foundation tier. High evidence but unactionable? Tier 3. Cheap but low signal? Doesn't make the cut.</p>

    <div class="axes">
      <div class="axis">
        <div class="axis-num">AXIS 01</div>
        <div class="axis-name">Causal evidence strength</div>
        <div class="axis-desc">How strong is the evidence that this metric causally predicts health outcomes? We prioritize randomized controlled trials and Mendelian randomization over observational cohorts, and observational cohorts over cross-sectional studies. Association is not causation — and most health tracking is built on association.</div>
      </div>
      <div class="axis">
        <div class="axis-num">AXIS 02</div>
        <div class="axis-name">Cost to measure</div>
        <div class="axis-desc">What does it actually cost to collect this data? A $40 blood pressure cuff that lasts 5 years costs $8/year. Your phone counting steps costs nothing. A DEXA scan costs $200 per data point. Cost per measurement, not cost per device.</div>
      </div>
      <div class="axis">
        <div class="axis-num">AXIS 03</div>
        <div class="axis-name">Actionability</div>
        <div class="axis-desc">Does knowing this number change what you should do? Blood pressure: yes, immediately and specifically. Cortisol from a single draw: almost never — the normal range is too wide and too context-dependent. This axis is where most "health optimization" tracking falls apart.</div>
      </div>
    </div>
  </div>

  <!-- Source Hierarchy -->
  <div class="method-section">
    <h2>Evidence hierarchy.</h2>
    <p>Not all studies are equal. A 1-million-participant meta-analysis of RCTs carries more weight than a 500-person cross-sectional survey. When we cite evidence for a metric's ranking, here's how we weight it:</p>

    <div class="hierarchy">
      <div class="hierarchy-row">
        <span class="hierarchy-rank">1</span>
        <span class="hierarchy-type">Randomized controlled trials (RCTs) + meta-analyses</span>
        <div class="hierarchy-bar"><div class="fill" style="width:100%"></div></div>
      </div>
      <div class="hierarchy-row">
        <span class="hierarchy-rank">2</span>
        <span class="hierarchy-type">Mendelian randomization studies</span>
        <div class="hierarchy-bar"><div class="fill" style="width:90%"></div></div>
      </div>
      <div class="hierarchy-row">
        <span class="hierarchy-rank">3</span>
        <span class="hierarchy-type">Prospective cohort studies (10K+ participants)</span>
        <div class="hierarchy-bar"><div class="fill" style="width:70%"></div></div>
      </div>
      <div class="hierarchy-row">
        <span class="hierarchy-rank">4</span>
        <span class="hierarchy-type">Smaller cohort / retrospective studies</span>
        <div class="hierarchy-bar"><div class="fill" style="width:45%"></div></div>
      </div>
      <div class="hierarchy-row">
        <span class="hierarchy-rank">5</span>
        <span class="hierarchy-type">Cross-sectional / expert consensus</span>
        <div class="hierarchy-bar"><div class="fill" style="width:25%"></div></div>
      </div>
    </div>

    <p>Every Tier 1 metric is backed by at least one large RCT or Mendelian randomization study. Most are backed by multiple.</p>
  </div>

  <!-- Full Ranking -->
  <div class="method-section">
    <h2>The full 40-metric ranking.</h2>
    <p>Tier 1 is the foundation — the 10 metrics with the strongest causal evidence, lowest cost, and highest actionability. Tier 2 enhances the picture. Tiers 3 and 4 are specialized or situational.</p>

    <table class="rank-table">
      <thead>
        <tr><th>#</th><th>Metric</th><th>Cost</th><th>Key evidence</th></tr>
      </thead>
      <tbody>
        <tr class="tier-header"><td colspan="4">Tier 1 — Foundation</td></tr>
        <tr><td>1</td><td>Blood pressure</td><td>$40 once</td><td>Each 20 mmHg &gt;115 SBP doubles CVD mortality (1M-participant meta-analysis). SPRINT: intensive lowering cut all-cause mortality 27%.</td></tr>
        <tr><td>2</td><td>Lipid panel + ApoB</td><td>$30–50/yr</td><td>ApoB causally linked to atherosclerosis (Mendelian randomization, Ference 2017). Statins reduce CV events ~22% per 1 mmol/L LDL reduction (CTT, 170K+).</td></tr>
        <tr><td>3</td><td>Metabolic panel</td><td>$40–60/yr</td><td>96M Americans prediabetic. IR precedes diabetes by 10–15 years (Whitehall II). DPP: lifestyle intervention reduced progression 58%.</td></tr>
        <tr><td>4</td><td>Family history</td><td>Free</td><td>Parental CVD &lt;60 doubles risk (Framingham). One-time collection. Captures inherited risk + shared environment.</td></tr>
        <tr><td>5</td><td>Sleep regularity</td><td>Free</td><td>Most irregular quintile: 20–48% higher mortality (Windred, UK Biobank, 72K). Regularity predicts mortality &gt; duration.</td></tr>
        <tr><td>6</td><td>Daily steps</td><td>Free</td><td>Each +1K steps = ~15% lower mortality (Paluch, Lancet 2022, 47K). Benefits plateau ~10K.</td></tr>
        <tr><td>7</td><td>Resting heart rate</td><td>Free</td><td>RHR 71–80 = 51% higher mortality vs 51–60 (Copenhagen City Heart Study). Trend over decade predicts mortality (HUNT, 30K).</td></tr>
        <tr><td>8</td><td>Waist circumference</td><td>$3</td><td>INTERHEART: waist-to-hip ratio is 1 of 9 factors explaining 90% of MI risk (27K, 52 countries).</td></tr>
        <tr><td>9</td><td>Medication list</td><td>Free</td><td>Contextual. Statins affect lipids, beta-blockers suppress HR/HRV, metformin alters glucose. Without this, other data gets misread.</td></tr>
        <tr><td>10</td><td>Lp(a)</td><td>$30 once</td><td>20% have elevated Lp(a) — independent causal CVD risk factor. &gt;90% genetic, doesn't change. One test, forever.</td></tr>

        <tr class="tier-header"><td colspan="4">Tier 2 — Enhanced picture</td></tr>
        <tr><td>11</td><td>VO2 max</td><td>Free</td><td>Strongest modifiable mortality predictor. Elite fitness = 80% lower mortality vs low (Mandsager, 122K).</td></tr>
        <tr><td>12</td><td>HRV trends</td><td>Free</td><td>32–45% increased CV risk with low HRV (Fang 2023, 50K+). Use 7-day rolling, not single readings.</td></tr>
        <tr><td>13</td><td>hs-CRP</td><td>$20/yr</td><td>JUPITER: normal LDL + elevated CRP = 44% CV event reduction with statin.</td></tr>
        <tr><td>14</td><td>Liver enzymes</td><td>Included</td><td>GGT independently predicts CV mortality + diabetes (Lee 2007, Framingham).</td></tr>
        <tr><td>15</td><td>CBC</td><td>Included</td><td>RDW predicts all-cause mortality (Patel 2009). Safety net screening.</td></tr>
        <tr><td>16</td><td>TSH</td><td>$20/yr</td><td>12% lifetime prevalence. Subclinical hypothyroidism associated with CHD (Rodondi 2010, 55K).</td></tr>
        <tr><td>17</td><td>Vitamin D + Ferritin</td><td>$40–60</td><td>42% of US adults vitamin D deficient. Ferritin &lt;30 = depleted iron stores. Cheap to fix.</td></tr>
        <tr><td>18</td><td>Weight trends</td><td>$20–50</td><td>Progressive drift is the signal. 5–10 lb/year increase stronger than absolute weight.</td></tr>
        <tr><td>19</td><td>PHQ-9</td><td>Free</td><td>88% sensitivity/specificity for major depression. Depression raises CVD risk 80% (Nicholson 2006).</td></tr>
        <tr><td>20</td><td>Zone 2 cardio</td><td>Free</td><td>150–300 min/week = largest mortality reduction (Ekelund 2019, 44K).</td></tr>

        <tr class="tier-header"><td colspan="4">Tier 3 — Optimization</td></tr>
        <tr><td>21</td><td>Strength training frequency</td><td>Free</td><td>30–60 min/week = 10–17% lower mortality (Momma 2022, 480K+).</td></tr>
        <tr><td>22</td><td>Body fat %</td><td>$25–200</td><td>Better than BMI but bioimpedance varies 3–5% by hydration.</td></tr>
        <tr><td>23</td><td>Hormones</td><td>$100–200</td><td>Symptom-driven. 20–30% diurnal variation in testosterone.</td></tr>
        <tr><td>24</td><td>B12, folate, iron</td><td>$40–80</td><td>B12 deficiency: 6% under 60, 20% over 60. Irreversible neuro damage if prolonged.</td></tr>
        <tr><td>25</td><td>eGFR (kidney)</td><td>Included</td><td>15% of US adults have CKD, 90% unaware.</td></tr>
        <tr><td>26</td><td>Supplement stack</td><td>Free</td><td>Contextual — explains anomalous lab values.</td></tr>
        <tr><td>27</td><td>Diet patterns</td><td>Free</td><td>Pattern-level captures the signal. Macro tracking has 30–50% inaccuracy.</td></tr>
        <tr><td>28</td><td>Homocysteine</td><td>$30–50</td><td>Predicts CVD/dementia but lowering it hasn't improved outcomes (HOPE-2).</td></tr>
        <tr><td>29</td><td>Sleep stages</td><td>Free</td><td>Consumer wearables: 60–80% accuracy vs polysomnography. Directional only.</td></tr>
        <tr><td>30</td><td>Respiratory rate</td><td>Free</td><td>Passive illness signal. Narrow normal range (12–20) makes small changes meaningful.</td></tr>

        <tr class="tier-header"><td colspan="4">Tier 4 — Specialized / Situational</td></tr>
        <tr><td>31</td><td>ECG / rhythm</td><td>Free</td><td>High value &gt;55 or with AF risk factors (5x stroke risk). Low value for young adults.</td></tr>
        <tr><td>32</td><td>Readiness scores</td><td>Wearable</td><td>Proprietary, opaque, not peer-reviewed. Track underlying data instead.</td></tr>
        <tr><td>33</td><td>Mood tracking</td><td>Free</td><td>Can reinforce rumination in anxiety-prone individuals. Offer cautiously.</td></tr>
        <tr><td>34</td><td>Visceral fat (direct)</td><td>$100–200</td><td>Proxied well by waist circumference ($3).</td></tr>
        <tr><td>35</td><td>Lean mass (DEXA)</td><td>$100–200</td><td>Valuable &gt;50 or during weight loss. Low routine value for younger adults.</td></tr>
        <tr><td>36</td><td>Symptoms log</td><td>Free</td><td>High value but compliance drops after 2–4 weeks.</td></tr>
        <tr><td>37</td><td>Cortisol</td><td>$50–100</td><td>Single-point nearly useless. Wide normal range, affected by everything.</td></tr>
        <tr><td>38</td><td>OxLDL</td><td>$40–60</td><td>Not recommended by any major CV guidelines. Poor assay standardization.</td></tr>
        <tr><td>39</td><td>Cancer markers (PSA)</td><td>$20–40</td><td>Risk of net harm. PSA: ~27 overdiagnoses per death prevented.</td></tr>
        <tr><td>40</td><td>Therapy engagement</td><td>Free</td><td>Contextual profile field, not a tracked metric.</td></tr>
      </tbody>
    </table>
  </div>

  <!-- Where tracking is counterproductive -->
  <div class="method-section">
    <h2>Where more data causes harm.</h2>
    <p>Baseline's credibility depends on not over-medicalizing healthy people. We intentionally exclude or down-weight metrics where the expected value of testing is negative.</p>

    <div class="counter-list">
      <div class="counter-item">
        <span class="counter-icon">&times;</span>
        <div class="counter-text"><strong>PSA / CA-125 (cancer markers).</strong> Population screening leads to overdiagnosis cascades. PSA: ~27 men overtreated for every 1 death prevented. CA-125 definitively does not reduce ovarian cancer mortality (UKCTOCS 2021, 200K women).</div>
      </div>
      <div class="counter-item">
        <span class="counter-icon">&times;</span>
        <div class="counter-text"><strong>CGMs for non-diabetics.</strong> No evidence that glucose variability in healthy people has clinical significance. Documented increase in food anxiety and orthorexic tendencies.</div>
      </div>
      <div class="counter-item">
        <span class="counter-icon">&times;</span>
        <div class="counter-text"><strong>Cortisol (single draw).</strong> Wide normal range, affected by sleep, stress, time of day, caffeine. Creates false certainty from a single number. Diurnal curves are $200–400 and still hard to interpret.</div>
      </div>
      <div class="counter-item">
        <span class="counter-icon">&times;</span>
        <div class="counter-text"><strong>Proprietary composite scores.</strong> Oura "Readiness," Whoop "Recovery" — opaque algorithms, not peer-reviewed, not clinically validated. Track the underlying data (HRV, RHR, sleep) instead.</div>
      </div>
      <div class="counter-item">
        <span class="counter-icon">&times;</span>
        <div class="counter-text"><strong>Detailed calorie/macro tracking.</strong> 30–50% underestimation even when actively logging (Lichtman, NEJM 1992). Associated with disordered eating in susceptible individuals. Pattern-level is enough.</div>
      </div>
    </div>
  </div>

  <!-- Design principles -->
  <div class="method-section">
    <h2>Scoring design principles.</h2>
    <p>These principles guide how coverage scores are weighted:</p>

    <p><strong>1. Foundation first.</strong> A person with blood pressure, lipids+ApoB, metabolic panel, family history, and Lp(a) has more health insight than someone with 10 wearable metrics but no blood work.</p>

    <p><strong>2. One-time data has disproportionate value.</strong> Family history and Lp(a) are collected once and permanently change your risk model. The scoring system strongly incentivizes these.</p>

    <p><strong>3. Wearable data is context, not core.</strong> Sleep, steps, RHR, and HRV make blood work actionable — they correlate habits with biomarker changes. High-ROI because they're passive, but they don't score above core clinical data.</p>

    <p><strong>4. Actionability gates inclusion.</strong> If knowing a metric doesn't change what you should do, it gets weighted lower regardless of predictive power. Homocysteine is a good example: strong predictor, but lowering it hasn't improved outcomes.</p>

    <p><strong>5. Never recommend things that can harm.</strong> The coverage score should never push someone toward a test where the expected value is negative.</p>
  </div>

  <!-- Sources -->
  <div class="method-section">
    <h2>Major references.</h2>
    <p class="sources">
      Prospective Studies Collaboration (1M participants) &middot;
      CTT Collaboration (170K+) &middot;
      SPRINT Trial &middot;
      Diabetes Prevention Program &middot;
      Framingham Heart Study &middot;
      UK Biobank &middot;
      HUNT Study (30K) &middot;
      Copenhagen City Heart Study &middot;
      JUPITER Trial &middot;
      CANTOS Trial &middot;
      INTERHEART (27K, 52 countries) &middot;
      Ference et al. 2017 (Mendelian randomization) &middot;
      Paluch et al., Lancet 2022 (47K) &middot;
      Momma et al., BJSM 2022 (480K+) &middot;
      Windred et al., Sleep 2024 (72K) &middot;
      Mandsager et al., JAMA 2018 (122K) &middot;
      Ekelund et al. 2019 (44K) &middot;
      Fang et al. 2023 (50K+) &middot;
      Nicholson et al. 2006 &middot;
      Rodondi et al. 2010 (55K) &middot;
      UKCTOCS 2021 (200K)
    </p>
  </div>

</div>

<!-- CTA -->
<div class="method-cta">
  <div class="container">
    <h2>See where you stand.</h2>
    <p>Calculate your coverage score in 60 seconds.</p>
    <a href="/baseline/#score-section" class="cta-btn">Calculate your score &rarr;</a>
  </div>
</div>

<!-- Footer -->
<footer>
  <div class="container">
    <p>
      Built in San Francisco with love &middot; <a href="https://x.com/a_e_deal" target="_blank" rel="noopener">@a_e_deal</a><br>
      Local-first. Your health data never touches our servers.
    </p>
  </div>
</footer>

</body>
</html>
